This content is from: Premium Biopharma Deals Offer Hope for Future Public Listings Investors are cautiously optimistic that the sector’s long drought could be coming to an end. By Stephen Taub March 27, 2023
This content is from: Portfolio A New, Esoteric Royalty Market Is Poised to Take Off About a dozen companies planning to go public via an IPO or SPAC are planning on using tax receivable agreements, which are now a $30 billion market, according to Parallaxes Capital. By Michael Thrasher February 15, 2023
Sponsored The 10 Themes That Could Make or Break an EM Renaissance Sponsored by Federated Hermes March 20, 2023
This content is from: Culture In the Hunt for Fraud, the Red Flags Start With the Auditor With its Adani report, Hindenburg zeroed in on the tiny firm’s thin staff and client roster. By Richard Teitelbaum March 08, 2023
This content is from: Corner Office PE-Backed Companies Outperform Peers, But What Happens After Sponsors Leave? Growth slows at companies once their private equity bosses exit, but new research finds they are still better off than those never taken over by buyout firms. By Hannah Zhang January 03, 2023
This content is from: Portfolio The Alts Investments BlackRock’s Avoiding — And the Ones It Can’t Get Enough Of “I do think in private equity, you’ve absolutely seen a shift in sentiment, particularly in the larger end of the market,” says Edwin Conway. By Julie Segal December 12, 2022
